comscoreHormonal Therapy

Hormonal Therapy

175 Research news
Adding 2 Years of Ovarian Suppression to Tamoxifen Improves Survival in Premenopausal Women With Early-Stage Breast Cancer

Treating premenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer with tamoxifen plus 2 years of ovarian suppression after surgery offers better disease-free survival than tamoxifen alone.

Sep 25, 2019 | Diagnosis and Hormonal Therapy
Antidepressant Duloxetine Eases Joint Pain Caused by Aromatase Inhibitors

The antidepressant duloxetine can ease joint pain in women diagnosed with early-stage, hormone-receptor-positive breast cancer who are taking an aromatase inhibitor.

Postmenopausal Women Benefit From Longer Hormonal Therapy

Taking Arimidex for 3 years after 5 years of tamoxifen reduced the risk of the cancer coming back in women diagnosed with hormone-receptor-positive breast cancer.

Older Women More Likely to Have Chemo-Related Cognitive Problems

Being older and having lower cognitive reserve levels may increase the risk of cognitive problems during and after chemotherapy.

Arimidex and Aromasin Equally Good at Reducing Recurrence Risk

A new study shows that Arimidex and Aromasin are equally good at reducing the risk of recurrence in postmenopausal women diagnosed with early-stage, hormone-receptor-positive breast cancer.

Tamoxifen Reduces Recurrence Risk for More Than 10 Years

Research has confirmed that tamoxifen reduces breast cancer recurrence risk during the standard 5 years of treatment and that recurrence risk stays lower during the next 5 years after tamoxifen treatment ends.

Experimental Abemaciclib Improves Outcomes in Advanced-Stage, Hormone-Receptor-Positive Disease

Results from a third study show that the experimental targeted therapy medicine abemaciclib improved progression-free survival in postmenopausal women diagnosed with hormone-receptor-positive, HER2-negative, advanced-stage breast cancer.

Sep 14, 2017 | Diagnosis and Hormonal Therapy
Is There a Link Between Hormonal Therapy Treatment and Diabetes?

A study suggests that women treated with hormonal therapy for breast cancer are more likely to develop diabetes compared to women not treated with hormonal therapy.

Jun 29, 2018 | Hormonal Therapy
Oncotype DX May Help Make Treatment Decisions for Breast Cancer That's Metastatic at Diagnosis

A study suggests that the Oncotype DX test can offer relevant information about cancer progression and 2-year survival rates for women diagnosed with de novo stage IV cancer.

Two Years of Tamoxifen After Surgery Offers Long-Term Survival Benefits

Taking tamoxifen for 2 years after surgery offers long-term survival benefits for premenopausal women diagnosed with early-stage, estrogen-receptor-positive disease compared to no treatment after surgery.

10 Years of Femara Better Than 5 for Early-Stage, Hormone-Receptor-Positive Disease

Ten years of Femara offers more benefits than 5 years.

Jun 16, 2016 | Diagnosis and Hormonal Therapy
Paxil May Ease Hot Flashes

Two studies suggest that a low dose of the antidepressant medicine Paxil can lower the number and severity of hot flashes in some women.

Risk-Reducing Effects of Arimidex for High-Risk Postmenopausal Women Last Years After Treatment Stops

Postmenopausal women at high risk for breast cancer who hadn't been diagnosed continued to get risk-reducing benefits for at least 11 years after they stopped taking Arimidex preventively.

Dec 19, 2019 | Hormonal Therapy
Too Many Women Stop Taking Tamoxifen Early

Many women stop taking adjuvant hormonal therapy medicine earlier than prescribed by their doctors.

Jan 22, 2007 | Diagnosis and Hormonal Therapy
U.S. Task Force Recommends Offering Hormonal Therapy Medicine to Women With High Risk for Breast Cancer

The U.S. Preventive Services Task Force has recommended that women with a high risk of breast cancer but who haven't been diagnosed be offered medicines that can lower that risk.

Oct 14, 2013 | Hormonal Therapy
Aromasin Plus Ovarian Suppression Better Than Tamoxifen for Premenopausal Women With Hormone-Receptor-Positive, HER2-Negative Disease With High Recurrence Risk

Premenopausal women diagnosed with early-stage, hormone-receptor-positive, HER2-negative breast cancer with a high risk of recurrence benefit the most from Aromasin plus ovarian suppression.

Apr 19, 2016 | Diagnosis and Hormonal Therapy
Diagnosed Young Women Concerned About Fertility Skip Tamoxifen

Concerns about fertility caused about 30% of younger women diagnosed with hormone-receptor-positive, early-stage breast cancer to skip or stop taking tamoxifen.

Telephone Counseling Helps Women Taking Femara Lose Weight

A small study has found that a telephone counseling program helped overweight postmenopausal women diagnosed with early-stage breast cancer who were taking Femara lose weight.

Jul 1, 2014 | Diagnosis and Hormonal Therapy
Women Stop Taking Hormonal Therapy Too Soon Because of Side Effects

Side effects cause many women to stop taking hormonal therapy medicine earlier than prescribed a new study reports.

About 25% of Women Either Don't Start or Don't Finish Hormonal Therapy

A study suggests that about 25% of women who are prescribed hormonal therapy to reduce the risk of recurrence after surgery either don't start taking the medicine or stop taking it early.

Apr 19, 2013 | Diagnosis and Hormonal Therapy
Adding Kisqali Improves Overall Survival in Younger Women With Advanced-Stage Hormone-Receptor-Positive Breast Cancer

Results from the MONALEESA-7 trial show that adding Kisqali to hormonal therapy and ovarian suppression significantly improves overall survival in premenopausal women diagnosed with advanced-stage, hormone-receptor-positive, HER2-negative breast cancer.

Women Without Prescription Drug Coverage Less Likely to Start Hormonal Therapy

A study has found that women diagnosed with early-stage, hormone-receptor-positive breast cancer with no prescription drug coverage were less likely to start hormonal therapy than women who had insurance coverage for prescription drugs.

ASCO Issues Guidelines on Using Biomarkers to Make Adjuvant Treatment Decisions for Women Diagnosed With Early-Stage Invasive Disease

ASCO has put out new guidelines on using biomarkers to make decisions about treatments after surgery for women diagnosed with early-stage invasive breast cancer.

Showing 24 of 175